Nanatinostat

Liver cells damaged by diet-driven metabolic dysfunction are a risk for liver cancer. Viracta Therapeutics closed a phase II trial for a lymphoma treatment. Jimmy Carter impacted cancer immunotherapy awareness. Stem cell transplants for blood cancers are declining. Direct-to-consumer cancer predisposition tests have pitfalls. Pembrolizumab insights for breast cancer treatment emerged. A California oncologist settled insider trading allegations. Evidence may explain varied treatment responses. 10 clinical studies by 2025 could impact cancer. Immuno-oncology to drive drug innovation. Advanced breast cancer may signal heart disease.

Viracta Therapeutics, facing financial constraints, closed its phase 2 lymphoma trial to explore strategic alternatives, following layoffs and focusing on its lead program, nana-val, for PTCL. Despite promising phase 2 results, the company aims to conserve resources, continuing nana-val assessment in a phase 1b/2 trial for EBV nasopharyngeal carcinoma.

Viracta Therapeutics, Inc. is exploring strategic alternatives to maximize value, including mergers or sales, and has closed its NAVAL-1 trial for Nana-val in EBV+ lymphomas to conserve resources, emphasizing no new safety concerns.

Viracta Therapeutics, Inc. announced its Board of Directors is exploring strategic alternatives, including mergers or sales, to maximize value. The company has closed its NAVAL-1 trial for Nana-val in EBV+ lymphomas, not due to safety concerns, to conserve resources during this review.

Viracta Therapeutics, Inc. announced its Board of Directors is exploring strategic alternatives, including mergers or sales, to maximize value. The company will close its NAVAL-1 trial to conserve resources, emphasizing this decision is not due to safety concerns.

The 'Post-Transplant Lymphoproliferative Disorder - Pipeline Insight, 2024' report by ResearchAndMarkets.com details 3+ companies and 3+ pipeline drugs for PTLD, covering drug profiles, therapeutic assessment, and inactive products. Key players include Viracta Therapeutics with Nana-Val (Nanatinostat and Valganciclovir), focusing on novel treatments. The report highlights ongoing clinical trials, collaborations, and emerging trends in PTLD therapeutics.